First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes

NCT04880291 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Diseases
Diabetic Nephropathies
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases

Interventions

DRUG: GFB-024
DRUG: Placebo

Sponsor

Goldfinch Bio, Inc.